NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 14, 2025 16:03 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
February 05, 2025 16:04 ET
|
NurExone Biologic Inc
NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
January 21, 2025 16:20 ET
|
NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
NurExone Biologic Secures Master Cell Bank
January 08, 2025 16:12 ET
|
NurExone Biologic Inc
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
December 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 13, 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
November 01, 2024 16:50 ET
|
NurExone Biologic Inc
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
October 23, 2024 02:56 ET
|
NurExone Biologic Inc
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 26, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M